Literature DB >> 3610932

Carnitine metabolism during exercise in patients with peripheral vascular disease.

W R Hiatt, D Nawaz, E P Brass.   

Abstract

The distribution between carnitine and the acyl derivatives of carnitine reflects changes in the metabolic state of a variety of tissues. Patients with peripheral vascular disease (PVD) develop skeletal muscle ischemia with exertion. This impairment in oxidative metabolism during exercise may result in the generation of acylcarnitines. To test this hypothesis, 11 patients with PVD and 7 age-matched control subjects were evaluated with graded treadmill exercise. Subjects with PVD walked to maximal claudication pain at a peak O2 consumption (VO2) of 19.9 +/- 1.3 ml X kg-1 X min-1 (mean +/- SE). Control subjects were taken to a near-maximal work load at a VO2 of 31.3 +/- 1.0 ml X kg-1 X min-1. In patients with PVD, the plasma concentration of total acid-soluble, long-chain acylcarnitine and total carnitine was increased at peak exercise compared with resting values. Four minutes postexercise, the plasma short-chain acylcarnitine concentration was also increased. In control subjects taken to the higher work load, only the long-chain acylcarnitine concentration was increased at peak exercise. In patients with PVD, plasma short-chain acylcarnitine concentration at rest was negatively correlated with subsequent maximal walking time (r = -0.51, P less than 0.05). In conclusion, acylcarnitines increased in patients with PVD who walked to maximal claudication pain, whereas control subjects did not show equivalent changes even when taken to a higher work load. The relationship between short-chain acylcarnitine concentration at rest and subsequent exercise performance suggests that repeated episodes of ischemia may cause chronic accumulation of short-chain acylcarnitine in plasma in proportion to the severity of disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610932     DOI: 10.1152/jappl.1987.62.6.2383

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  12 in total

1.  Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.

Authors:  Emile R Mohler; John L Gainer; Kim Whitten; Luis H Eraso; Porama Koy Thanaporn; Timothy Bauer
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

2.  Characterization of the peripheral artery disease symptom experience.

Authors:  Erica N Schorr; Cynthia Peden-McAlpine; Diane Treat-Jacobson; Ruth Lindquist
Journal:  Geriatr Nurs       Date:  2015-04-29       Impact factor: 2.361

3.  Femoral Artery Occlusion Increases Muscle Pressor Reflex and Expression of Hypoxia-Inducible Factor-1α in Sensory Neurons.

Authors:  Wei Gao; Jianhua Li
Journal:  J Cardiovasc Dis       Date:  2013-10

4.  Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study.

Authors:  N Corsico; A Nardone; M R Lucreziotti; L G Spagnoli; D Pesce; T Aureli; M E Di Cocco; A Miccheli; F Conti; E Arrigoni Martelli
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

Review 5.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

Review 6.  Physiology in medicine: peripheral arterial disease.

Authors:  Matthew D Muller; Amy B Reed; Urs A Leuenberger; Lawrence I Sinoway
Journal:  J Appl Physiol (1985)       Date:  2013-08-22

7.  Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state.

Authors:  W R Hiatt; J G Regensteiner; E E Wolfel; L Ruff; E P Brass
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

Review 8.  Mitochondrial Bioenergetics in the Metabolic Myopathy Accompanying Peripheral Artery Disease.

Authors:  Victoria G Rontoyanni; Omar Nunez Lopez; Grant T Fankhauser; Zulfiqar F Cheema; Blake B Rasmussen; Craig Porter
Journal:  Front Physiol       Date:  2017-03-13       Impact factor: 4.566

Review 9.  Safety and efficacy of cilostazol in the management of intermittent claudication.

Authors:  Yung-Wei Chi; Carl J Lavie; Richard V Milani; Christopher J White
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Altered Metabolomic Profile in Patients with Peripheral Artery Disease.

Authors:  Ahmed Ismaeel; Marco E Franco; Ramon Lavado; Evlampia Papoutsi; George P Casale; Matthew Fuglestad; Constance J Mietus; Gleb R Haynatzki; Robert S Smith; William T Bohannon; Ian Sawicki; Iraklis I Pipinos; Panagiotis Koutakis
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.